Skip to main content
Atomwise logo

Atomwise

Updated Mar 24, 2026

Everything you need to know about Atomwise — from their $219M in funding to who's backing them.

🇺🇸United StatesSeries BAI Healthcare

Out of 100

🇺🇸

HQ

United States

🗓

Founded

2012

💰

Raised

$219M

🏷️

Stage

Series B

👥

Team

75

Atomwise is an artificial intelligence company focused on drug discovery and development, founded in 2012 and headquartered in the United States. The company uses AI and computational chemistry to identify and optimize potential drug candidates, reducing the time and cost associated with traditional pharmaceutical research methods. Atomwise's platform applies machine learning algorithms to screen

Is this your company? Claim it →

Key Facts

  • Atomwise has raised a total of $219M in disclosed funding across 3 funding rounds.
  • Atomwise was founded in 2012 by Abraham Heifets and is headquartered in United States.
  • Atomwise employs approximately 75 people.
  • Atomwise operates in the AI Healthcare category and is currently at the Series B stage.
  • Atomwise has an Awaira Score of 53/100, ranking it among the tracked AI companies on Awaira.
  • Atomwise's most recent funding round was a Series B of $123M closed in August 2020, led by Temasek.

Source: Awaira · Updated Mar 24, 2026

N/A

Post-money

$219M

All rounds

53/100

2012

75 employees

Strengths

Established market presence (founded 2012)

Based in the US, the world's largest AI market

Considerations

!

Valuation not publicly disclosed

Analysis based on publicly available data. Not investment advice.

3

Total Rounds

$84M

Avg Round Size

8.8yr

Funding Span

Atomwise raised 3 rounds over 8.8 years, averaging $84M per round — a pace of roughly one round every 35 months.

⚠️ ESTIMATE
💵Est. Annual Revenue
$20M–$100M estimated ARR

Awaira estimate based on public data. Not financial advice.

How does Atomwise stack up against competitors?

MetricAtomwiseButterfly NetworkTempusAlan
Awaira Score53/10085/10084/10083/100
Total Raised$219M$370M$1.05B$750M
ValuationN/A$957M$8.1B$5.83B
StageSeries BPublicPublicSeries D
Founded2012201120152016
Employees75500-10002500500-1000
Country🇺🇸🇺🇸🇺🇸🇫🇷
A

Abraham Heifets

Founder & CEO

View founder profile →
StageSeries B
Employees75
Country🇺🇸 United States
Connect
Inactive
3 rounds
Series BLatest

Led by Temasek

$123M

Aug 2020

Series A

Led by Khosla Ventures

$45M

Jan 2015

Seed

Undisclosed

Jan 2012

Frequently Asked Questions

What is Atomwise's valuation?
No public valuation has been disclosed yet. The company operates in the AI Healthcare space and may reveal this in a future round.
Who invested in Atomwise?
Known backers include Temasek, B Capital Group, Khosla Ventures, Data Collective. These investors have supported the company through various funding rounds.
When did Atomwise last raise funding?
The most recent round was a Series B of $123M, closed in August 2020. The round was led by Temasek.
How many employees does Atomwise have?
The headcount sits at approximately 75 employees, based in United States.
What does Atomwise do?
Atomwise is an artificial intelligence company focused on drug discovery and development, founded in 2012 and headquartered in the United States. The company uses AI and computational chemistry to identify and optimize potential drug candidates, reducing the time and cost associated with traditional pharmaceutical research methods. Founded in 2012, Atomwise is categorized under AI Healthcare.
Who founded Atomwise?
The company was started by Abraham Heifets in 2012 in United States. Abraham Heifets serves as Founder & CEO.
Is Atomwise profitable?
Profitability details aren't publicly disclosed. The company has raised $219M in total funding and is currently at the Series B stage.
Where is Atomwise headquartered?
Headquarters are in United States 🇺🇸. The company operates in the AI Healthcare sector and was established in 2012.
⚔️

Compare Atomwise

See how Atomwise stacks up against competitors in valuation, funding, team size, and Awaira Score.

Browse all comparisons →